Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
about
Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysisCancer as a metabolic diseaseMicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1Evaluation of protein biomarkers of prostate cancer aggressivenessThe putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progressionUSP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2AA high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complexPTEN inhibits BMI1 function independently of its phosphatase activityThe histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expressionMiR-15a and MiR-16 control Bmi-1 expression in ovarian cancerE2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferasesMel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cellsALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcomeContribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesisNew molecularly targeted therapies for lung cancerMel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteinsEvaluation of reference-based two-color methods for measurement of gene expression ratios using spotted cDNA microarrays.Actions of Thyroid Hormone Analogues on ChemokinesUbiquitin-specific peptidase 22 functions and its involvement in diseaseTargeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapyGenome-wide analysis of microRNA and mRNA expression signatures in cancerBiological features and biomarkers in hepatocellular carcinomaMolecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancersEmerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachAurora B hyperactivation by Bub1 overexpression promotes chromosome missegregationEpigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancerT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancerB-cell-specific Moloney murine leukemia virus integration site 1: potential stratification factor and therapeutic target for epithelial ovarian cancerHippo/YAP pathway for targeted therapyHedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cellsDeficiency in the nuclear-related factor erythroid 2 transcription factor (Nrf1) leads to genetic instabilityA novel five gene signature derived from stem-like side population cells predicts overall and recurrence-free survival in NSCLCAn RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancerInhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancerDiscovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomyA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesDevelopment of multigene expression signature maps at the protein level from digitized immunohistochemistry slidesPolycomb silencers control cell fate, development and cancerBreast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
P2860
Q21136141-D6942484-857B-4941-9069-D9987B3BE545Q21245061-C72BC303-18C8-4A51-AB2C-B900C9BA6032Q21245764-93A70E0B-EF7E-4179-99C1-A2FC54E61054Q21261257-28BB4CC1-BE15-48F7-9D3E-42A5FA8D1387Q24307439-9DA1A26F-AED6-49C3-9F92-EC42807D668BQ24311562-8F135150-ED5D-4B30-8DFD-4212A7E31C22Q24314096-7808A67D-FF07-4502-BFF0-91251777F7E7Q24315949-49289A98-51B6-4F18-A7FB-72EA7CC618B6Q24318500-031D047C-E05C-413B-B9F1-26B32F179673Q24632636-7FF8387D-9158-453E-A3E3-AF2BA26B2268Q24646412-288EBD2A-6843-49DD-9586-1C397708BCBBQ24654211-2F89FD30-BD58-4929-B259-7BFEB6D69699Q24657877-F84C4CF8-5E35-4A57-B9FD-4ABD0B6FB773Q24675945-EFDBF127-006D-4A95-A5E3-8A1428F043AFQ24680988-BADF1285-5BE7-4D46-93B5-3AF55106C300Q24681882-C0A176FC-829F-4B36-9A94-F9ED1FD55EABQ25255703-BFDC108F-E0F8-4871-9D1C-594A2B9BA45EQ26738767-DB32195E-F5EF-4F4C-BAB5-F1D8573A59ECQ26750743-E07F005B-49A0-42D7-8126-64853D6B7963Q26775961-B4A2253D-8258-4ABF-AFA1-D7D4B94B6590Q26795603-5BA97829-F131-4B93-BB92-AB52848ADC89Q26799462-2E422B0A-081B-41F7-95EB-1E9C48154CF5Q26822406-39866842-D51B-4D80-9BBC-436A29D19652Q26849477-50A80123-7AD8-4C6F-A634-797951599E2CQ26995347-CBBAEEFD-F084-40EA-8AD7-6D85E39251B0Q27022720-F6556CCA-5BE2-481F-B8CC-6FB672313303Q27335110-D1AAE196-49FC-443B-AAA2-EA39FD631873Q27438119-CB611B74-99DA-4261-A6B5-D59E02FF258CQ28075362-85C0078F-BC75-4613-8DAD-72500E4C912FQ28088294-3D2380E7-56BF-4E47-B90E-6E70BB2AB4E5Q28246460-5A240811-C480-4522-8C44-D50F22E41892Q28274930-ECE9A500-6138-44AE-828E-92E3BD67C4FDQ28387995-0932D6A8-A9E8-45CA-8B3D-9163888394B9Q28484295-836F44E9-9771-4760-B651-738FB1BA790DQ28488474-E1F4CB58-7BA3-4259-B865-67D2B6B8E428Q28534277-793B91FA-559D-4DCB-B5D9-73AACA0E4D4FQ28540936-04BD6E07-A4FE-4381-9DBC-B21594352B37Q28731283-DD9EAB4B-E843-42FB-962F-7FB3CBBB8FD5Q29619697-F4E1329D-DC17-47F1-AA14-549F328B5A55Q29622952-B8169C63-F5FB-4D39-9048-C1AC28BFA21A
P2860
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Microarray analysis identifies ...... with multiple types of cancer
@ast
Microarray analysis identifies ...... with multiple types of cancer
@en
Microarray analysis identifies ...... with multiple types of cancer
@en-gb
Microarray analysis identifies ...... with multiple types of cancer
@nl
type
label
Microarray analysis identifies ...... with multiple types of cancer
@ast
Microarray analysis identifies ...... with multiple types of cancer
@en
Microarray analysis identifies ...... with multiple types of cancer
@en-gb
Microarray analysis identifies ...... with multiple types of cancer
@nl
prefLabel
Microarray analysis identifies ...... with multiple types of cancer
@ast
Microarray analysis identifies ...... with multiple types of cancer
@en
Microarray analysis identifies ...... with multiple types of cancer
@en-gb
Microarray analysis identifies ...... with multiple types of cancer
@nl
P2093
P2860
P3181
P356
P1476
Microarray analysis identifies ...... with multiple types of cancer
@en
P2093
Anna B Glinskii
Gennadi V Glinsky
Olga Berezovska
P2860
P304
P3181
P356
10.1172/JCI23412
P407
P577
2005-06-01T00:00:00Z